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Objectives—Contrast-enhanced ultrasonography (CEUS) allows the study of
vascularization of secondary liver lesions. The Cyberknife (Accuray, Inc, Sunny-
vale, CA) is a therapeutic method that allows a tumor target to be subjected to a
high radiant dose gradient. This prospective pilot study aimed to demonstrate
the concordance of CEUS versus contrast-enhanced computed tomography
(CECT) in determining the stability or disease progression of secondary liver
lesions after treatment with the Cyberknife.
Methods—Twenty-four patients were consecutively enrolled, and 3 different
operators evaluated the CEUS images and the intermodality concordance with
CECT. All patients received CEUS at 1 and 2 months after the Cyberknife ther-
apy. The intermodality agreement was evaluated by the Cohen κ coefficient and
a multivariate analysis according to the method of Janson and Olsson (Educ Psy-
chol Meas 2001; 61:277–289).
Results—Forty secondary liver lesions were detected and treated. Forty-one
CECT and 51 CEUS examinations were performed without any adverse events
in the 24 patients. The intermodality agreement rates, calculated for the operators
as Cohen κ values, were κ = 1.00, 0.881, and 0.767, respectively. The multivariate
analysis of intermodality agreement showed an almost perfect value (ι = 0.841).
Conclusions—This pilot study found excellent diagnostic correspondence
between CEUS and CECT in the evaluation of local disease stability or pro-
gression after Cyberknife therapy in liver metastases. These findings suggest
that CEUS could play an important role in the surveillance of these patients
because of its high accuracy and reproducibility, thus reducing the need
for CECT.
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ultrasonography; liver cancer; liver metastases; liver ultrasonography;
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A bdominal ultrasonography (US) usually represents the first-step diagnostic procedure to investigate liver diseases.Contrast-enhanced ultrasonography (CEUS) using micro-
bubble contrast agents has increased its performance, allowing for
a dynamic evaluation of the vascular patterns of solid organs and
Received January 24, 2018, from the Gastro-
enterology Unit, Modena University Hospital,
Modena, Italy (M.M., B.L., M.L., B.C., A.C.);
Digestive Endoscopy Unit, Carpi Hospital,
Azienda Unità Sanitaria Locale, Modena,
Italy (T.G.); General Cardiology Unit (S.L.);
Gastroenterology Unit, Azienda Ospedaliera
Universitaria Careggi Hospital, Florence,
Italy (M.R.B.); Department of Gastroenterol-
ogy, Valiant Clinic, Dubai, United Arab
Emirates (V.A.). Manuscript accepted for
publication June 4, 2018.
We thank Andrew Jamieson, MB, ChB
(Hons), BSc (Hons), PhD, MRCP (UK),
FRCPGlasg, consultant physician and endocri-
nologist, honorary senior lecturer in medicine,
for revision of English style and grammar.
Address correspondence to Maria Marsico,
MD, Gastroenterology Unit, Modena Univer-
sity Hospital, Via San Giovanni del Cantone
23, 41121 Modena, Italy.
E-mail: ma.marsico@libero.it
Abbreviations
CECT, contrast-enhanced computed tomo-
graphy; CEUS, contrast-enhanced ultra-
sonography; CT, computed tomography;
SBRT, stereotaxic body radiotherapy; US,
ultrasonography
doi:10.1002/jum.14734
© 2018 by the American Institute of Ultrasound in Medicine | J Ultrasound Med 2019; 38:649–655 | 0278-4297 | www.aium.org
lesions. Contrast-enhanced US also provides the
opportunity to carefully investigate and characterize
small hepatic lesions previously evaluated only by
computed tomography (CT) or magnetic resonance
imaging.1–4 For these reasons, this method is widely
used for the screening and surveillance of primary or
secondary hepatic lesions and could be potentially
used in their follow-up after chemotherapy or radio-
therapy.
Stereotaxic body radiotherapy (SBRT), called
Cyberknife (Accuray, Inc, Sunnyvale, CA, USA), is
a technique using robotic equipment with high spa-
tial and topographic resolution for full-body radio-
surgery. This technology uses image guidance,
robotic technology, and dynamic target tracking
with automatic correction of breathing movements
to allow submillimetric accuracy together with a
high radiation gradient. The result is the opportu-
nity to irradiate the tumor target with a high dose
of radiation while safeguarding surrounding
organs.5,6 In the setting of primary and secondary
liver lesions, the Cyberknife allows delivery of dou-
ble the radiation dose compared with conventional
radiotherapy.7,8 This ability provides an opportunity
to treat liver lesions that are not amenable to sur-
gery with greater accuracy and potency than con-
ventional radiotherapy and a less-invasive approach
compared with thermoablation or cryotherapy.
Conventionally, 2 months after treatment, a follow-
up evaluation is performed by CT with contrast
media; however, although that method is widely
used,9 more recent studies have raised concern
regarding the sensitivity of evaluations of arterial
perfusion of hepatic lesions. In addition, CT is
expensive, leads to considerable radiation exposure,
and carries the risk of an iodine contrast allergic
reaction.
Contrast-enhanced US10 could be a valuable
alternative to CT in the evaluation of liver lesions
after SBRT with the Cyberknife, since, when directed
to specific target lesions, it allows an accurate evalua-
tion of the vascular pattern. In addition, CEUS has a
low cost and is very safe, although it can be operator-
dependent. The primary aim of this pilot study was
to evaluate the concordance of CEUS compared with
contrast-enhanced computed tomography (CECT) in
the evaluation of secondary liver lesions at baseline
and after SBRT with the Cyberknife.
Materials and Methods
Study Design
This work was a pilot single-center prospective study
to compare the concordance of CEUS with CECT in
the evaluation of characteristics and potential local
progression/regression of secondary liver lesions after
SBRT with the Cyberknife. The primary objective
was to evaluate the concordance among CEUS and
CECT (intermodality agreement) for detection of
the stability or progression of hepatic lesions 2 months
after therapy. Secondary objectives were the potential
yield of a further CEUS evaluation 1 month after the
treatment to detect earlier disease progression or
treatment failure and the interobserver agreement of
the CEUS findings among 3 different physicians to
evaluate the reproducibility.
Disease progression was defined by the all of fol-
lowing parameters: size increase, increase in lesion
numbers, and persistent arterial contrast enhance-
ment (wash-in) and wash-out in the portal phase.
Disease stability was defined as stable or reduction of
lesion size, stable or reduction of lesion numbers and
lack of wash-in and wash-out contrast enhancement
compared with baseline. The parameters collected
were interpreted according to the Modified Response
Evaluation Criteria in Solid Tumors.
Patient Population
Consecutive patients with liver metastasis undergoing
treatment with SBRT were enrolled from September
2015 at the Cyberknife Center of the Villa Ulivella
and Villa Glicini Institute of Assistance and Care
(Florence, Italy). Informed consent was obtained
from all patients. Exclusion criteria for the study
were those related to CECT (pregnancy, moderate-
to-severe renal insufficiency, and allergy to iodine
media) and CEUS (cardiac shunt, myocardial ische-
mia, and allergy to sulfur). All procedures followed
were in accordance with the ethical standards of the
committee responsible for human experimentation
and with the Declaration of Helsinki, sixth revi-
sion, 2008.
Methods
Before SBRT, all patients had baseline (T0) CEUS
for evaluation of the characteristics and dimensions of
the liver lesions at the Outpatient Clinic of the
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Department of Gastroenterology of the Azienda
Ospedaliera Universitaria Careggi Hospital. The US
was performed with a ProSound α7 system (Hitachi-
Aloka, Tokyo, Japan) equipped with a 3.75–7.5-MHz
transducer (UST 91-30 multifrequency convex
abdominal transducer). For each investigation, a base-
line evaluation in B-mode was performed to visualize
the lesion and detect the optimal scanning window
for the CEUS. The contrast media used was 5 mL of
sulfur hexafluoride (SonoVue; Bracco SpA, Milan,
Italy) followed by 10 mL of saline injected into the
cephalic or basilic vein at the level of the elbow cubi-
tal fold. A full digital recording of the complete exam-
ination was performed each time. The sizes of lesions
were calculated during the B-mode examination and
during the arterial phase of CEUS. As reported in the
literature, we considered the arterial phase the time
within 30 seconds from injection of contrast media,
the portal phase up to 2 minutes after injection, and
the late phase from 2 to 5 minutes after injection
(Figure 1). The baseline CEUS was done blinded to
the results of CECT.
For the purpose of fine targeting the SBRT treat-
ment, gold fiducial markers (Gold Anchor 22G;
Naslund Medical AB, Huddinge, Sweden) were posi-
tioned in the proximity of the lesion (Figure 2) to be
detected by CT and used by the Cyberknife imaging-
tracking system for precise localization of the lesions.
Subsequently, 1 to 3 SBRT sessions were performed,
following the standard procedure protocol. A follow-
up evaluation of the treatment was performed after
2 months (T2) by CECT up to May 2016.
All patients also received CEUS at 1 (T1) and
2 (T2) months after the SBRT procedure (Figures 3
and 4). At T1, all patients with disease progression
were scheduled for an earlier evaluation by CECT
and subsequent oncologic management. In contrast,
patients with stable findings compared with baseline
were evaluated by CEUS and CECT at 2 months
(T2). The CEUS and CECT were always performed
within a time window of 5 days.
Figure 1. Liver metastasis evaluated by CEUS before Cyberknife.
The US evaluation was performed up to 435 seconds after Sono-
Vue injection. The liver lesion remained hypovascular with periph-
eral enhancement.
Figure 2. Hyperechoic gold fiducial marker positioned in the prox-
imity of liver metastasis.
Figure 3. Liver metastasis evaluated 2 months after radiation ther-
apy. The lesion was hypovascular with contrast enhancement of
tumor septa.
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The CEUS examinations were performed by a
single physician (T.G.), holder of a master’s degree in
abdominal US from the Italian Scientific Society of
Medical Ultrasonography at the Department of Gas-
troenterology of the Azienda Ospedaliera Universi-
taria Careggi Hospital. The interobserver evaluation
of the digital recordings was performed by 2 other
physicians (M.R.B. and M.M.) from the Azienda
Ospedaliera Universitaria Careggi Hospital and the
Azienda Ospedaliera Universitaria Maggiore Hospital
(Bologna, Italy), respectively, holders of the same
master’s degree.
The CECT scans were performed with the CT
equipment of each referral center by a standard
3-phase protocol using iodine contrast agents
(Iomeron, 400 or 100 mL; Bracco Spa; or Ultravist,
370 or 100 mL; Bayer Healthcare, Berlin, Germany)
and full digital recording. The CECT scans were eval-
uated by experienced independent radiologists in
each referral center.
Statistical Analysis
The intermodality agreement of the imaging modali-
ties for each operator was evaluated by the Cohen κ
coefficient,11 whereas the concordance for CEUS
among 3 physicians was evaluated by the Fleiss κ
coefficient.12 The concordance between CEUS and
CECT among all of the operators was evaluated by a
multivariate analysis according to the method of Jan-
son and Olsson13 and expressed as the ι coefficient.
The ι and kappa values obtained were evaluated as
follows: no concordance, κ = 0; low concordance,
κ = 0.1 to 0.20; insufficient concordance, κ = 0.21 to
0.40; sufficient concordance, κ = 0.41 to 0.60; good
concordance κ = 0.61 to 0.80; and excellent concor-
dance, κ greater than 0.80, as suggested by Landis
and Koch.14 The statistical significance was set at
P < .05. The statistical analysis was performed with
SPSS software for Windows (IBM Corporation,
Armonk, NY) and R Statistics (Bell Laboratories, Inc,
Madison, WI) by T.G. and reviewed by the senior
investigator (V.A.).
Results
Twenty-four consecutive patients were enrolled in
the study (10 female and 14 male; mean age ± SD,
64 ± 12.5 years). All patients had liver metastasis
from colorectal (10), breast (2), prostate (2), gastro-
intestinal stromal (2), stomach (2), melanoma (1),
pancreatic (1), thyroid (1), adrenal gland (1), gall-
bladder (1), and ovarian (1) cancers. All patients had
failure or disease recurrence despite previous thera-
pies, including chemotherapy, radiotherapy, surgery,
or a combination of these according to the cancer
characteristics. Nine patients had a single lesion,
whereas the remaining patients had 2 or more lesions,
ranging in size from 0.8 to 7 cm. In total, 40 liver
lesions were detected and treated: 3 in the left lobe
and 37 in the right lobe. The mean tumor size was
30.75 ± 15.8 mm. A further patient had complete
structural derangement of the liver and was excluded
from the study because of rapid disease deterioration
and death.
Of the 24 enrolled patients, 17 completed the
follow-up, and 3 were excluded because of rapid dis-
ease progression from the tracking CT scan to the
start of SBRT; 3 other patients died before the end of
follow-up. Another patient was excluded because of
failure of gold marker positioning for technical
reasons.
When evaluated by CEUS at 1 month (T1), 7 of
17 patients (41%) showed disease progression and
were referred to the oncologist for different therapeu-
tic management; 3 of 17 patients showed disease pro-
gression when evaluated by CEUS at 2 months (T2).
In 7 of 17 patients (41%), there was no disease
Figure 4. Liver metastasis evaluated 2 months after radiation ther-
apy. The lesion remained hypovascular, and disease progression
was shown by the increased diameter of the lesion.
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progression after treatment at the T2 evaluation. No
adverse events related to the use of contrast media
were reported in a total of 41 CECT and 51 CEUS
examinations.
Interobserver Agreement
The interobserver concordance for CECT computed
as the Fleiss κ was excellent (κ = 0.84). The concor-
dance for the CEUS findings was evaluated at T0, T1,
and T2 among the physician performing the US stud-
ies (operator 1) and the other 2 who evaluated the
digital recordings. The concordance at T0, T1, and
T2 was excellent (κ = 1.00 and 0.84) and good
(κ = 0.75), respectively.
Intermodality Agreement
The agreement between CECT and CEUS was evalu-
ated at baseline and 2 months after the SBRT; when
the evaluation at 2 months was missing because of
disease progression, the evaluation of concordance
was performed at the 1-month follow-up. More spe-
cifically, the findings of 10 patients were compared at
2 months, whereas the remaining 7 patients were
evaluated at 1 month because of disease progression.
At 2 months of follow-up in 7 patients, the lesions
were stable, whereas in the remaining 3 patients, dis-
ease progression was found.
The concordance at baseline (T0) of the CECT
with the physician who performed the CEUS (opera-
tor 1) was excellent (κ = 1.00). In the 17 patients
evaluated after the treatment, the concordance among
the physician who performed the CEUS (operator 1)
with the CECT findings was excellent (κ = 1.00).
The intermodality agreement among CECT and
CEUS was also calculated for the other 2 physicians
who evaluated the digital recordings of the US. The
concordance was κ = 1.00 and 0.881 (excellent) for
operator 2 and κ = 1.00 and 0.767 (good) for opera-
tor 3 at T0 and the T1 and T2 follow-ups, respec-
tively. The multivariate analysis considering all
3 operators evaluating CEUS compared with CECT
resulted in an ι value of 0.841.
Discussion
Stereotaxic body radiotherapy is an emerging treat-
ment modality frequently adopted to treat primary
and secondary tumors that are not amenable to surgi-
cal treatment and after failure or relapse following
chemotherapy.15 The evaluation of the efficacy or dis-
ease progression is usually performed with CECT,
which is considered the reference standard. In this
pilot prospective study, we compared the concor-
dance of CEUS with CECT as an alternative imaging
modality in patients with liver metastasis, and we
found an excellent agreement (Cohen κ = 1.00).
Contrast-enhanced CT is surely the most-used
imaging procedure for staging and follow-up of onco-
logic patients, thus ensuring a progressive increase in
radiation exposure in the last decades. From 1998 to
2007, the proportion of adverse events correlated
with radiation exposure for diagnostic and therapeutic
procedure increased in the United States by 150%
(from 6% to 15%).16 In western and developed coun-
tries, the total radiation exposure for patients due to
medical procedures is comparable with the yearly
absorption of total radiation from the atmosphere,
the cosmos, and radionuclides.17 More specifically,
CT scanning is responsible for two-thirds of the
entire radiation exposure from medical procedures
and represents a considerable cost for health ser-
vices.18 The progressive rise in health costs strongly
suggests an exploration and validation of new
methods in terms of safety and cost without jeopar-
dizing their diagnostic accuracy. Contrast-enhanced
US is a method that has been extensively validated
for the evaluation of benign and malignant hepatic
lesions and, more specifically, hepatocarcinoma and
liver metastasis.19 It is considered the first-choice
method for evaluation of liver lesions when there is
no need for panoramic imaging of the parenchyma,
with the additional advantages of low cost and
absence of radiation exposure. Moreover, contrary to
the iodine contrast agents used for CECT, the media
used for CEUS have no renal excretion or risk of
allergic reactions.
To the best of our knowledge, this work was the
first study aimed at investigating the concordance of
CEUS with CECT in the context of patients after
SBRT, and it showed excellent concordance. Some
studies already have been published comparing CEUS
with CECT (as the reference standard) in the follow-
up of patients after radiofrequency treatment of pri-
mary renal or liver cancers, also showing a high
degree of concordance, similar to our experience.20–23
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In a recent study by Kong et al24 regarding the con-
cordance among CEUS and CECT in patients after
radiofrequency treatment of renal lesions, the concor-
dance was also 100%.
Potential limitations of CEUS and US in general
are the experience of the operator, the opportunity to
accurately identify lesions, and the concordance
among different investigators.25 In this study, in all
patients, CEUS successfully recognized and ade-
quately visualized the lesions. In addition, in all
4 patients in whom no uptake of the US contrast
agent was shown, the CECT scans confirmed the
absence of contrast enhancement, and with either
imaging modality, the response to treatment was
managed only on the basis of the size and number of
nodules. More importantly, the agreement of CEUS
findings among 3 different physicians was evaluated:
1 was directly performing the procedures, whereas
the other 2 evaluated the digital recordings. The over-
all agreement with CECT was 0.84, whereas for
CEUS at different time points, it was 0.91 (ι values
from the multivariate analysis).
Another important achievement of the study was
that at the T1 evaluation with CEUS after 1 month of
follow-up, 7 of 17 patients (41%) already had disease
progression; therefore, an earlier change in the onco-
logic plan was made. If these data can be confirmed,
then the follow-up after the procedure could be man-
aged differently with more frequent and repeated
CEUS evaluations, given the low cost and lack of
radiation.26 Finally, it is remarkable to note that no
adverse events were reported, as expected, from the
CEUS contrast media.
This pilot study had some limitations. The sam-
ple size was small because of the short time window
for patient enrollment (9 months, as required by the
department’s Study Committee), the slow enrollment
of patients for Cyberknife, which is still a procedure
under validation, and the deterioration and disease
progression with incomplete follow-up durations in
some patients. In addition, a test of concordance
among radiologist could not be performed because of
the different equipment in the respective hospitals.
However, the important strength of the study was the
high concordance among 3 different physicians in
evaluating CEUS and comparing CEUS with CECT.
This pilot study also clearly showed high diagnos-
tic concordance among CEUS and CECT at baseline
and after SBRT with the Cyberknife in patients with
liver metastasis, with accurate evaluation of the effi-
cacy of the therapy (obtained in 59% of cases) or dis-
ease progression. In addition, because of the high
interobserver concordance of the CEUS findings, the
low cost and lack of radiation exposure, this method
could replace CECT in the follow-up of Cyberknife
therapy efficacy. Also, CEUS could be performed
more frequently during follow-up to detect a lack of
efficacy and disease deterioration earlier. We can
speculate that after reference imaging with CECT at
the beginning of treatment, we could follow the thera-
peutic evolution only with CEUS; thus, CECT would
be performed only intermittently. Further controlled
studies with larger sample sizes are awaited to confir-
mation our preliminary findings.
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